Loading...
•
Sep 30, 2022
Novavax Q3 2022 Earnings Report
Announced financial results and operational highlights for the third quarter ended September 30, 2022
Key Takeaways
Novavax reported its Q3 2022 financial results, highlighting the expansion of their COVID-19 vaccine's label, achievement of policy recommendations globally, and expansion of clinical evidence supporting their vaccine technology.
Expanded COVID-19 Vaccine in Adult Population Aged 18 and Older
Expanded COVID-19 Vaccine in Adolescent Population Aged 12 Through 17
Continued COVID-19 Vaccine Manufacturing and Supply
Progressed COVID-19 Clinical Development Program
Novavax
Novavax
Forward Guidance
Novavax is refining full year 2022 total revenue guidance to approximately $2.0 billion.